NCT04213170

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Prospective Phase II Clinical Study of Sintilimab Combined With Bevacizumab for Driving Gene-negative, Asymptomatic Brain Metastases From Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective phase II clinical study to assess the efficacy of Sintilimab combined with Bevacizumab for driving gene-negative, asymptomatic brain metastases from non-small cell lung cancer by intracranial ORR(iORR),also iPFS,ORR and PFS.The safety and tolerability is evaluated as well.

Conditions

• Brain Metastases
• Non Small Cell Lung Cancer
• Sintilimab
• Bevacizumab

Interventions

Type	Name	Description
DRUG	sintilimab	Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d

Timeline

• Start date: 2019-04-29
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2019-12-30
• Last updated: 2019-12-30

Locations

1 site across 1 country: China